Valion Bio (VIBO) Q1 2026 earnings summary

Executive summary

• Completed corporate transformation and rebranding to Valion Bio, focusing on clinical-stage biopharmaceuticals anchored by Entolimod, a leading TLR5 agonist with Fast Track and Orphan Drug designations from the FDA.

• Integrated Velocity Bioworks as a wholly owned biomanufacturing subsidiary, now operational and representing the most immediate revenue opportunity.

• Strategic focus on commercial oncology supportive care, national medical countermeasures, and expanded government partnerships and funding.

• Acquired Scorpius Holdings' CDMO assets, vertically integrating manufacturing and expanding into contract services.

• Appointed Michael K. Handley as CEO and Melinda Lackey as General Counsel and SVP of Legal Affairs in 2026.

Significant events and developments

• Secured a non-clinical evaluation agreement with NIAID for gastrointestinal acute radiation syndrome, with NIAID fully funding BLA-enabling in vivo programs.

• Presented Entolimod to the Department of War and received interest from Ukraine's Ministry of Health for national stockpile inclusion.

• Opened the Velocity Bioworks facility in San Antonio, Texas, marking the activation of domestic biomanufacturing capabilities.

• Validated Entolimod inventory for distribution and sale, triggering a $750,000 milestone liability.

• Achieved 200-fold manufacturing scale-up at 50-liter fermentation for Entolimod.

Financial highlights

• Total operating expenses for Q1 2026 were $5.6 million, up from $1.4 million in Q1 2025, mainly due to Velocity Bioworks integration and rebranding.

• Research and development expense rose to $1.9 million from $0.3 million year-over-year, reflecting new biomanufacturing costs and expanded headcount.

• Selling, general, and administrative expense increased to $3.8 million from $1 million, with $1.7 million attributed to Velocity Bioworks and $0.4 million in executive severance.

• Net loss for Q1 2026 was $6.2 million ($2.23/share), compared to $1.5 million ($2.52/share) in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $7.2 million, down from $12.6 million at year-end 2025; operating cash use increased to $5 million from $0.9 million.